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Abstract The Fork head box C1 (FOXC1) gene is
overexpressed in multiple malignant tumors and is func-
tionally correlated with tumor progression. However, its’
role in oral squamous cell carcinoma (OSCC) is still
unclear. Recent studies have revealed that many long non-
coding RNA (lncRNAs) cooperate with adjacent coding
genes and form a functional ‘‘lncRNA-mRNA pair’’. In this
study, we report a new lncRNA FOXC1 upstream tran-
script (FOXCUT) that was remarkably overexpressed in 23
OSCC patients, as was the adjacent FOXC1 gene. The
expressions of FOXC1 and FOXCUT were positively
correlated. When the expression of FOXCUT was down-
regulated by small interfering RNA (siRNA), the expres-
sion of FOXC1 was also decreased. Moreover, in OSCC
cells Tca8113 and SCC-9, down-regulation of either
FOXC1 or FOXCUT by siRNA could inhibit cell prolif-
eration and cell migration in vitro and was accompanied
with a reduction of MMP2, MMP7, MMP9, and VEGF-A.
In conclusion, FOXC1 may be co-amplified with FOXCUT
in OSCC, and both of them may be functionally involved
in the tumor progression of OSCC. This provides evidence
that both FOXC1 and FOXCUT may serve as novel bio-
markers and therapeutic targets in OSCC patients who
overexpress this ‘‘lncRNA-mRNA pair’’.
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Introduction
Oral squamous cell carcinoma (OSCC) is one of the most
aggressive neoplasms among head and neck malignant
tumors [1]. Despite considerable recent advances in treat-
ment, the prognosis of advanced OSCC remains poor. Many
studies have revealed multiple genetic, multistep changes in
the development of the OSCC [2, 3]. Therefore, a better
comprehension of the molecular mechanisms underlying
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OSCC is necessary for selecting suitable predictive bio-
markers and seeking emerging tailored therapeutic strategies.
The fork head box C1 (FOXC1) gene, a member of the
FOX family, is located on chromosome 6p25 [4] and is a
transcriptional factor that regulates a wide array of biological
processes including the maintenance of differentiated cell
states, embryogenesis, tumorigenesis, and tumor progression,
such as epithelial-mesenchymal transition (EMT) and cell
migration [5–7]. Several recent studies have reported that
FOXC1 overexpression is strongly correlated with poor sur-
vival in the patients of multiple cancers such as breast cancer,
pancreatic ductal adenocarcinoma, non-small cell lung can-
cer, or hepatocellular carcinoma [6–11]. However, overex-
pression of FOXC1 has not been reported in OSCC yet.
Because transcriptional factors normally do not act alone,
it is likely that FOXC1 is a component of a larger complex
that regulates the initiation of transcription, and it is impor-
tant to find the molecules that interact with FOXC1 to impact
tumorigenesis and tumor progression. Lately, transcriptome
wide analysis has shown that[90 % of the human genomic
DNA is transcribed into non-coding RNAs (ncRNAs) that
lack protein-coding potential. Among those, long non-cod-
ing RNAs (lncRNAs) are those ncRNA transcripts ranging
from 200 bases to 100 kilo bases (kb) in length [12–15]. In
malignant tumors, numerous unique lncRNA molecules
have been found that are closely associated with the devel-
opment and progression of a variety of cancers [14].
Recent studies have revealed that a large proportion of
lncRNAs cooperate with adjacent protein-coding genes and
form ‘‘lncRNA-mRNA pairs’’ that impact their function.
Close relationships are often found between these lncRNAs
and their nearby mRNAs in expression or function. The
‘‘lncRNA-mRNA’’ pair is now regarded as a new form in the
very complex gene expression modulating network. [16].
Through bioinformatic analysis, we found an lncRNA tran-
scribed from the upstream region of FOXC1 promoter that we
named FOXC1 upstream transcript, or, FOXCUT. We specu-
lated that the divergent transcription of this lncRNA-mRNA pair
(FOXC1 and FOXCUT) may play an important role in OSCC.
In this study, we investigated the expression pattern of
FOXC1 and lncRNA-FOXCUT in OSCC tissues, the cor-
relation between the expression of this lncRNA-mRNA
pair, and the functional role of this pair in OSCC in vitro.
The aim of this study was to possibly identify a new
functional lncRNA-mRNA pair involved in OSCC.
Materials and methods
Patient samples
A total of 23 fresh OSCC tissue specimens together with
matched adjacent nontumorous tissue specimens were
collected from patients who underwent surgery in our
Hospital, China, between 2012 and 2013. The OSCC
diagnosis was histopathologically confirmed. None of the
patients received preoperative therapy before surgical
resection. All tissue specimens were immediately frozen
and stored in liquid nitrogen after surgery until the
extraction of total RNA. This research was approved by the
ethical committee of PLA General Hospital. The proce-
dures followed were in accordance with the ethical stan-
dards established by the Ethics Committee of our Hospital.
Cell line and cell culture
The human OSCC cell lines used were Tca8113, OSC-4,
SCC1, SCC2, SCC4, SCC9, CAL-27, UM1, and UM2. The
human hepatocellular carcinoma cell lines used were
SMMC7721, HCCLM3, HUH7, and HEPG2. The human
breast cancer cell lines used were MCF7, BT474, SKBR3,
HCC1187, and HCC1143. The normal human liver cell line
LO2, the normal human oral keratinocyte cell line HOK, and
the normal human breast cell MCF-10A were purchased from
American type culture collection (Manassas, VA, USA). The
Tca8113, CAL-27, MCF 10A, SMMC7721, HCCLM3,
HEPG2, and BT474 cells were incubated in DMEM medium
(Hyclone, Logan, UT) containing 10 % FBS (Invitrogen,
Carlsbad, CA) at 37 C with 5 % CO2. The OSC-4, SCC2,
SCC9, LO2, HCC1143, and SKBR3 cells were incubated in
PRMI-1640 (Gibco, American) containing 10 % FBS. The
SCC-4, MCF7, and HUH7 cells were incubated in DMEM:
F12 containing 10 % FBS. The HOK cells were incubated in
OKM containing growth factor. Approximately 5 % of
Tca8113 cells were plated into each well of 12-well plates at
least 24 h before transfection to achieve 30–50 % confluency.
Quantitative PCR
Total RNA was extracted from OSCC tumor tissues, mat-
ched adjacent normal tissues and OSCC cells using trizol
total RNA reagent (Invitrogen, Carlsbad CA). Primers were
obtained from Sheng Gong (Shanghai, China), and their
sequences are shown in Table 1. Quantitative PCR was
performed using the SYBR primescript RT-PCR kit (Ta-
kara, Ohtsu, Japan) in an Applied Biosystems 7500 Fluo-
rescent Quantitative PCR System (Applied Biosystems,
Foster City, CA). The reaction mixtures were incubated at
95 C for 30 s, followed by 40 amplification cycles of
95 C for 5 s and 60 C for 34 s. The comparative Ct
method was used to quantify relative expression of mRNA
and lncRNA. Expression level of the housekeeping gene,
b-actin, was used to normalize gene-of-interest expression.
The expression level of each target gene in a patient was
calculated as the ratio of target in tumor tissue/target in
nontumorous tissue [R (T/N)].
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Western blot assay
Cells were washed twice with chilled PBS and lysed directly
in wells by incubating with RIPA lysis buffer supplemented
with protease inhibitor (Roche) 48 h post-transfection.
Equal amounts of protein were size fractionated by SDS-
PAGE on 4–12 % Bis–Tris acrylamide NuPAGE gels in
MOPS SDS running buffer (Invitrogen), and transferred onto
a nitrocellulose membranes (Whatman) in NuPAGE transfer
buffer (Invitrogen) containing 10 % methanol. Membranes
were blocked with 5 % skimmed milk at room temperature
for 2 h, incubated overnight (4 C) with primary antibodies,
and then incubated with corresponding secondary antibody
for 60 min at room temperature.
Transfection of siRNA
The siRNA sequences were obtained from gene pharma
(Shanghai, China), including one negative control siR-
NA(NC siRNA) sequence, two lncRNA-FOXCUT siRNA
sequences, and two FOXC1 siRNA sequences. The target
sequences are shown in Table 2. siRNA transfection was
performed with X-treme GENE transfection reagent (Roche)
according to the manufacturer’s instructions. Approximately
5 % Tca8113 and SCC-9 cells were plated into each well of
12-well plates at least 24 h before transfection to achieve
30–50 % confluency. After two washes with PBS, the
Tca8113 cells in each group were transfected by NC siRNA,
FOXCUT siRNAs (si1, si2), or FOXC1 siRNAs (si1, si2) for
at least 48 h. After transfection, total cells were collected for
RNA isolation, cell proliferation assay, colony formation
assay, and scratch wound healing assay.
Cell proliferation assay
Cells proliferation was measured by MTS according to the
manufacturer’s protocol. In brief, after transfection, the
Tca8113 cells (2,000cells/well) were seeded into 96-well
plates. The cells were incubated for 0, 1, 2, or 3 days,
Then, 20 ll of MTS reagent (Promega) was added to each
well containing 100 ll culture medium, and the plates were
incubated routinely for 1 h at 37 C. The absorbance val-
ues of each well were measured with a universal microplate
reader at a wavelength of 490 nm.
Colony formation assay
Cells were trypsinized, counted, and seeded at a low den-
sity of 600 cells/well on six-well culture plates. Cells grew
undisturbed at 37 C in 5 % CO2 for 2 weeks and then
stained with crystal violet.
Scratch wound healing assay
Uniform wounds were made in Tca8113 epithelial mono-
layers grown on plastic 12-well plates using a pipette tip
Table 1 Primers for real-time
PCR analysis











Table 2 Target sequences for small interfering RNA analysis
Genename Sense strand Antisense strand
FOXC1 si 1 50rGrCrArGrUrArArUrUrGrCrUr
GrUrUrGrCrUrUrGrUrUrGTC
50rGrArCrArArCrArArGrCrArArArCrArGrCrArArUrUrArCrUrGrCrUrU
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before transfection. Microphotographs were taken at 0 h,
24 h, and 48 h after siRNA transfection.
Statistical analysis
Differences between groups were analyzed using Student’s
t test. Correlation between gene expression ratios was
studied by using Pearson’s correlation. Statistical analyses
were performed by using SPSS version 18.0 (SPSS, Chi-
cago, IL) and GraphPad Prism Software (GraphPad Soft-
ware, Inc., San Diego, CA). For all statistical analyses,
p \ 0.05 was considered statistically significant.
Results
FOXC1 and FOXCUT were co-overexpressed in OSCC
tissue specimens and OSCC cell lines
The FOXC1 mRNA and FOXCUT lncRNA expression
levels were assessed in a group of 23 patients with OSCC and
23 corresponding adjacent normal tissues by Real-Time
Quantitative PCR. We found that 19 of the 23 OSCC patients
(82.6 %, p \ 0.05) showed remarkably higher expression of
FOXC1 mRNA in tumor tissues than in noncancerous tissues
(Fig. 1a). In addition 21 of the 23 patients (91.3 %, p \ 0.05)
showed remarkably higher expression of FOXCUT lncRNA
in tumor tissues than in noncancerous tissues (Fig. 1b). The
relative expression of FOXC1 positively correlated with that
of FOXCUT in OSCC tissue samples. The expression levels
of FOXC1 mRNA and FOXCUT lncRNA were then evalu-
ated in a panel of OSCC cell lines, Tca8113, OSC-4, SCC1,
SCC2, SCC4, SCC9, CAL-27, UM1, UM2, and a normal
human oral keratinocyte cell line, HOK. The results showed
that FOXC1 and FOXCUT were both overexpressed in all
nine of the OSCC cell lines compared with the normal human
oral keratinocyte cell line HOK. To further confirm these
results, we also investigated the expression of FOXC1 and
FOXCUT in four hepatocellular cancer cell lines and five
breast cancer cell lines, and found that both FOXC1 and
FOXCUT expressions were higher in these cancer cells than
in normal cells. Moreover, among the nine OSCC cells lines,
Tca8113 and SCC-9 cells displayed the most apparent
FOXC1 and FOXCUT dual overexpression. Therefore, we
chose Tca8113 and SCC-9 as the candidate cells in the
FOXC1 and FOXCUT knock-down experiments.
Fig. 1 The lncRNA-FOXCUT and FOXC1 expression levels were
analyzed by real-time PCR in 23 OSCC tissue samples, 9 human
OSCC cell lines Tca8113,OSC-4, SCC1, SCC2, SCC4, SCC9, CAL-
27, UM1, and UM2; 4 human hepatocellular carcinoma cell lines,
SMMC7721, HCCLM3, HUH7, and HEPG2; 5 human breast cancer
cell lines MCF7, BT474, SKBR3, HCC1187, and HCC1143; and
normal human liver cells LO2, normal human oral keratinocyte cell
line HOK, normal human breast cell MCF-10A. a The expression
levels of FOXC1 in OSCC were significantly higher than those in
adjacent normal tissues by Real-Time Quantitative PCR, b the
expression levels of lncRNA FOXCUT were also higher than those in
adjacent normal tissues by Real-Time Quantitative PCR. c The
expression level of FOXC1 was significantly correlated with that of
lncRNA-FOXCUT (R = 0.7063 p \ 0.0001), d the expression levels
of FOXC1 mRNA and FOXCUT lncRNA were apparently elevated in
all the nine OSCC cell lines compared with normal human oral
keratinocyte cell line HOK. e, f additionally, the FOXC1 and
FOXCUT were co-overexpressed in all the hepatocellular carcinoma
cell lines and breast cancer cell lines than in the normal cells (*
indicates p \ 0.05)
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FOXC1 expression in Tca8113 cells was suppressed
by FOXC1 siRNA and FOXCUT siRNA
In Tca8113 cells, RNAi analysis was conducted to further
clarify the correlation between the expression of FOXCUT
and FOXC1. Real-time PCR was performed to evaluate the
expression of FOXC1 mRNA and FOXCUT lncRNA, and
western blot was performed to assess the expression of
FOXC1 protein. The results showed that the FOXC1
expression level was down-regulated in FOXC1 siRNA
groups compared with NC siRNA group (Fig. 2a, b). Both
FOXC1 siRNA1 and FOXC1 siRNA2 knockdown were
efficient; they were down-regulated by nearly 80 % (Fig. 2a).
Moreover, the FOXC1 expression levels were also
down-regulated in FOXCUT siRNA groups compared with
the NC siRNA group (Fig. 2c). The FOXCUT lncRNA
expression was decreased by almost 90 %, and the FOXC1
mRNA expression was also suppressed by approximately
70 % (Fig. 2c). The expression of FOXC1 protein was also
decreased, which was certified by western blot (Fig. 2d).
However, given that the FOXC1 expression was mark-
edly reduced by approximately 80 % in FOXC1 siRNA
groups (Fig. 2a), the FOXCUT expression levels did not
decrease together (Fig. 2a).
Knockdown of FOXC1 inhibited the cell proliferation
and migration ability in Tca8113 and SCC-9
To investigate the effects of FOXC1 knockdown on the
in vitro growth characteristics of the OSCC cell lines
Tca8113 and SCC-9, MTS and colony formation assays
were employed to assess cell proliferation ability, and a
scratch wound healing assay was performed to evaluate
cell migration ability.
The MTS results showed that cell proliferation was
inhibited in the FOXC1 siRNA groups (Fig. 3a, b,
p \ 0.05), and the number of colonies was also signifi-
cantly decreased in FOXC1 siRNA groups compared to the
NC siRNA group (Fig. 3c, d, p \ 0.05). The scratch wound
healing assay results showed that the cell migration was
also retarded by FOXC1 siRNAs (Fig. 3e, f).
Knockdown of FOXCUT inhibited the cell proliferation
and migration ability in Tca8113 and SCC-9
To further identify the function of FOXCUT, we also per-
formed an MTS assay, a colony formation assay and a scratch
wound healing assay after siRNA transfection. The results
showed that the growth ability of the Tca8113 and SCC-9
Fig. 2 The expression levels of
FOXC1 mRNA and FOXCUT
lncRNA in Tca8113 cells after
siRNA transfection. a The
expression levels of FOXC1 in
FOXC1 siRNA group were
significantly knocked down in
Tca8113 cells (* indicates
p \ 0.05), but the expression
lncRNA FOXCUT did not
decrease. b FOXC1 protein
expression also markedly
decreased in FOXC1 siRNA
group. c The expression levels
of both FOXCUT and FOXC1
were significantly knocked
down in FOXCUT siRNA group
(* indicates p \ 0.05).
d FOXC1 protein expression
also markedly decreased in
FOXCUT siRNA group
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Fig. 3 Knockdown of FOXC1 inhibited the cell proliferation and
migration ability in Tca8113 and SCC-9. a, b FOXC1 siRNAs
reduced the Tca8113 and SCC-9 cells growth compared with NC
siRNA in MTS assay. c, d The colony formation rates of Tca8113 and
SCC-9 cells were significantly decreased by FOXC1 siRNAs
(p \ 0.01). e, f The capacity of cell migration in FOXC1 siRNAs
groups was remarkably impaired
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cells was significantly inhibited by FOXCUT siRNA1
(Fig. 4a, b, c, d, p \ 0.05), and the cell migration capacity
was also retarded (Fig. 4e, f). These functional test results
following FOXCUT knockdown were in agreement with the
effects of FOXC1 knockdown on the in vitro growth char-
acteristics of Tca8113 and SCC-9 as shown above.
Fig. 4 Knockdown of FOXCUT inhibited the cell proliferation and
migration ability in Tca8113 and SCC-9. a, b FOXCUT siRNAs
reduced the Tca8113 and SCC-9 cells growth compared with NC
siRNA in MTS assay. c, d The colony formation rates of Tca8113 and
SCC-9 cells were significantly decreased by FOXCUT siRNAs
(p \ 0.01). e, f The capacity of cell migration in FOXCUT siRNA
groups was impaired
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Knockdown of FOXC1 and FOXCUT reduced
the expression of certain MMPs and VEGF-A
The matrix metalloproteinases (MMPs) have been identi-
fied as important indicators in OSCC cell migration [8],
[17]. Furthermore, MMP expressions, as well as some
angiogenesis factors such as VEGF-A, have correlated with
FOXC1 expression in cancers [7]. These findings prompted
us to evaluate the effect of FOXC1 and FOXCUT knock-
down on MMPs and VEGF-A expressions. The results of
real-time PCR and western blot showed that the expression
of MMP2, MMP7, and MMP9 were decreased concomi-
tantly with FOXC1 and FOXCUT knocking down (Fig. 5a,
b). In contrast, the expression of MMP1, MMP3, and
MMP13 were not affected by FOXC1 and FOXCUT
silencing. Additionally, the results also confirmed that the
expression level of angiogenesis factor VEGF-A was
reduced after FOXC1 and FOXCUT knockdown (Fig. 5a,
b), which may indicate a possible role for FOXC1 and
FOXCUT in tumor angiogenesis.
Discussion
OSCC is a complicated and multi-step malignant tumor
that results from a multitude of genetic mutations. Genetic
disorders in OSCC have been widely studied, and an
increasing number of tumor suppressor genes and onco-
genes have been identified that contribute to OSCC [18].
Previous investigations about OSCC-related genes are
mainly focused on protein-coding genes. Recently, an
emerging role for lncRNAs in various cancers has been
identified in an increasing number of studies. [14]. However,
the expression and functional role of most lncRNAs are still
unknown in the disease progression of OSCC.
In this study, we first identified a new lncRNA-mRNA
pair, FOXC1 and its adjacent lncRNA FOXCUT, as the
new form of cancer driver gene compound in OSCC.
FOXC1 was shown to be involved in the occurrence and
development of various tumors by affecting the cell pro-
liferation, epithelial-to-mesenchymal transition (EMT),
and cell migration [6, 19]. However, in OSCC, the role of
FOXC1 has not yet been identified. The function of
FOXC1 and the related possible regulatory mechanisms in
OSCC is necessary to be clarified.
FOXC1 upstream transcript (FOXCUT) is a FOXC1
adjacent lncRNA which belongs to a class of ncRNAs called
promoter upstream transcripts (PROMPTs) [20–22]. The
expression and function of PROMPTs are often associated
with the adjacent protein coding transcripts. Therefore, we
speculated that lncRNA-FOXCUT may regulate the cancer
cell growth characteristics of OSCC by regulating FOXC1.
Based on these finding, we investigated the expression
pattern of the lncRNA/mRNA gene pairs of lncRNA-FOX-
CUT and mRNA-FOXC1 in 23 OSCC tissue samples by real-
time PCR. The results showed that the expression level of
lncRNA-FOXCUT was positively correlated with FOXC1
mRNA. When the expression of FOXCUT was down-regu-
lated by siRNA, the expression of FOXC1 was also decreased.
However, the down-regulation of FOXC1 did not affect the
expression of lncRNA FOXCUT. It suggests that the
lncRNA-FOXCUT may be a regulator of FOXC1 gene
expression. However, lncRNAs can regulate adjacent protein-
coding gene activity by many different ways, and the specific
molecular mechanisms underlying the regulatory impact of
this lncRNA-mRNA pair has not been described in this study.
The real-time PCR results also showed that both the
lncRNA-FOXCUT expression and the mRNA FOXC1
expression were significantly elevated in OSCC tumor
tissues and OSCC cell lines compared with normal oral
Fig. 5 Effect of FOXC1 and
FOXCUT knockdown on the
expression of certain MMPs and
VEGF-A. a, b Real-time PCR
and Western blot examine
showed that the expressions of
MMP2, MMP7, MMP9, and
VEGF-A were apparently
decreased together with FOXC1
and FOXCUT knocking down
in the Tca8113 cell after
transfection
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cavity tissues and oral keratinocyte cell. For the first time,
we revealed that both the RNA of FOXCUT and FOXC1
can be stably detected, and both may serve as novel
molecular markers for OSCC.
In addition, we further explored a possible functional role
of this lncRNA-mRNA pair in OSCC cell growth charac-
teristics using siRNA. As mentioned above, in many other
malignant tumors, FOXC1 has been demonstrated to be a
cancer-related factor involved in tumor progression pro-
cesses such as cell proliferation and cell migration. There-
fore, we assessed the cell proliferation and migration ability
after FOXCUT/FOXC1 siRNA transfection by using MTS,
colony formation assay and scratch wound healing assay.
The results showed that the knockdown of either FOXCUT
or FOXC1by siRNA could inhibit the proliferation and
migration of OSCC cell Tca8113 and SCC-9.
MMPs are set of critical factors in the migration and
invasion of OSCC cells [17]. Expression of some MMPs
correlated with FOXC1 expression, such as MMP7 in
breast cancer [8] and MMP1, MMP2, MMP7, and MMP9
in hepatocellular cancer [7]. We hypothesized that these
MMPs may also be associated with the FOXC1 and
FOXCUT gene pair. Therefore, we determined the
expression of these MMPs by both mRNA and protein
levels after FOXC1 and FOXCUT down-regulation. In
accordance with our hypothesis, MMP2, MMP7, and
MMP9 expressions decreased together following both
FOXC1 and FOXCUT knockdown, which indicate that
these four MMPs could be involved in FOXC1/FOXCUT
gene-pair related function in OSCC cell migration.
EMT has been demonstrated to promote angiogenesis by
modulating factors such as VEGF-A [7]. Because FOXC1 is
an EMT-related gene, and the relationship between FOXC1
and VEGF-A has also been proved in hepatocellular cancer
[7], here, we also revealed that the knockdown of FOXC1/
FOXCUT gene pair could lead to VEGF-A down-regulation.
This may suggest a possible role for the FOXC1/FOXCUT
gene pair in tumor angiogenesis in OSCC.
In conclusion, these results suggest that in the lncRNA-
mRNA pair, FOXCUT and FOXC1 are both novel over-
expressed functional molecules in OSCC. This study is the
first to identify the expression and functional role of an
lncRNA-mRNA pair in OSCC. FOXCUT and FOXC1
could be represent the potential diagnostic markers and
therapeutic targets in the cancer clinic.
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